ACADIA PHARMACEUTICALS INC
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the Company’s last fiscal quarter, no Company director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the Exchange Act))adopted orterminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as those terms are defined in Item 408 of Regulation S-K, except:
On August 6, 2026, the Rule 10b5-1 trading arrangement, which was intended to satisfy the affirmative defense of Rule 10b5-1(c) and adopted by James Kihara, Senior Vice President, Finance, on December 9, 2025, wasterminated. The trading arrangement provided for the sale of up to 41,421 shares of our common stock. Prior to the termination, 11,421 shares were sold under the trading arrangement. The trading arrangement was scheduled to expire on March 9, 2027, or earlier if and when all transactions under the trading arrangement were completed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.